跳转至内容
Merck
CN

A74807

Sigma-Aldrich

4-氨基苯砜

97%

别名:

4,4′-二氨基二苯砜, 4,4′-磺酰基二苯胺, DDS, 双(4-氨基苯基)砜, 氨苯砜

登录查看公司和协议定价

关于此项目

线性分子式:
(H2NC6H4)2SO2
CAS Number:
分子量:
248.30
Beilstein:
788055
EC 号:
MDL编号:
UNSPSC代码:
12162002
PubChem化学物质编号:
NACRES:
NA.23
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

97%

表单

crystals

mp

175-177 °C (lit.)

SMILES字符串

Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2

InChI

1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2

InChI key

MQJKPEGWNLWLTK-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

4-氨基苯砜(DDS)是一种用于固化环氧树脂的二胺类固化剂。

应用

四官能环氧树脂可以与DDS混合,并且可以加热固化,用于油田应用。DDS也可用于固化氧化铁 (Fe2O3) 层状双氢氧化物基环氧树脂,形成阻燃环氧树脂纳米复合材料。它还可用作固化剂,固化用于制造阻燃环氧树脂/黏土纳米复合材料的双酚A (DGEBA)。

警示用语:

Danger

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 1B - STOT RE 2 - STOT SE 2

靶器官

Blood, Blood,spleen,Liver

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jaesung Seo et al.
Health and quality of life outcomes, 13, 138-138 (2015-09-05)
This paper aimed to employ subject matter experts (SMEs) to assess the extent to which the Korean version of the short-form of the OHIP (OHIP-14 K) is culturally valid and equivalent in Korean. We approached 17 bilingual Korean SMEs from
A novel high performance bismaleimide/diallyl bisphenol A (BMI/DBA)-epoxy interpenetrating network resin for rigid riser application.
Jena RK, et al.
Royal Society of Chemistry Advances, 5(97), 79888-79897 (2015)
Glass transition dependence of ultrahigh strain rate response in amine cured epoxy resins.
Knorr Jr DB.
Polymer, 53(25), 5917-5923 (2012)
F-R Zhang et al.
The New England journal of medicine, 369(17), 1620-1628 (2013-10-25)
Dapsone is used in the treatment of infections and inflammatory diseases. The dapsone hypersensitivity syndrome, which is associated with a reported mortality of 9.9%, develops in about 0.5 to 3.6% of persons treated with the drug. Currently, no tests are
Ernest Güell et al.
Palliative & supportive care, 13(2), 295-303 (2014-04-26)
We aimed to address the prevalence of desire-to-die statements (DDSs) among terminally ill cancer patients in an acute palliative care unit. We also intended to compare the underlying differences between those patients who make desire-to-die comments (DDCs) and those who

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持